Preventing CMV After First Kidney Transplant
Treatments studied
Part of Infections, Kidney & urinary clinical trials.
This trial tests a new medicine, Leymovir, against a standard one, Valganciclovir, to prevent a common virus infection (CMV) after a first kidney transplant. It may help you avoid CMV-related illness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- This is your first kidney transplant.
- You are between 0 and 7 days after the kidney transplant.
- You are not currently on dialysis or plasmapheresis.
- You do not have a history of CMV infection or disease in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called letermovir to see if it can help prevent a common virus called CMV from causing problems after your transplant. It's for people who have had a kidney or liver transplant and carry the virus.
This trial tests two ways to prevent CMV in kidney transplant patients who are at high risk. It compares giving antiviral medicine preemptively (based on regular blood tests) versus giving it as prophylaxis (starting right after transplant). The goal is to see which approach prevents CMV infection better.
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
This study compares two medications, letermovir and valganciclovir, to see which works better at preventing CMV infection in people who have received a kidney transplant and have previously been exposed to the virus. Taking part may help reduce the risk of a serious infection after transplant.
This study tests a new drug called letermovir, given after a lung transplant, to see if it prevents CMV infection better than the current standard drug, valganciclovir. If you're at high risk for CMV, this trial could help protect you from this common post-transplant infection.
Hear when a new Kidney Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.